Micro-PET for pre-clinical molecular imaging research in Hong Kong

Professor Khong, Pek Lan   (Principal Investigator (PI))

Professor Tsao George Sai Wah   (Co-principal investigator)

Professor Wu Ed Xuekui   (Co-principal investigator)

Professor Tse Hung Fat   (Co-principal investigator)

Professor Leung Anskar Yu Hung   (Co-principal investigator)

Professor Wong Wing-tak   (Co-principal investigator)

Dr Zhu Hongyun June   (Co-principal investigator)

Dr Chan Lawrence, Wing-chi   (Co-principal investigator)

Professor Nicholls John Malcolm   (Co-principal investigator)

Professor Man Kwan   (Co-principal investigator)

Professor Ma Stephanie Kwai Yee   (Co-principal investigator)

Dr Wong Cesar Sze-Chuen   (Co-principal investigator)

Professor Ng Irene Oi Lin   (Co-principal investigator)

Dr Chang Raymond Chuen Chung   (Co-principal investigator)

Professor Yung Benjamin, Yat-ming   (Co-principal investigator)

Dr Lui Wai Yan Vivian   (Co-principal investigator)

Professor Ngan Hextan Yuen Sheung   (Co-principal investigator)

Dr Mak Henry Ka Fung   (Co-principal investigator)

Dr Lee Elaine Yuen Phin   (Co-principal investigator)

Professor Wong Ian Chi Kei   (Co-principal investigator)

36

2015-06-30

8001486

Micro-PET for pre-clinical molecular imaging research in Hong Kong

molecular imaging, positron emission tomography, pre-clinical, radiotracer

Imaging,Molecular Diagnostics

C7018-14E

Collaborative Research Fund (CRF) - Major Equipment Project

2014

Completed

1) To establish a research platform in pre-clinical molecular imaging using a micro-PET, backed by an already operational academic cyclotron and radiotracer lab, and with the potential of synergistic and parallel clinical molecular imaging research in the established PET/CT unit in HKU. 2) To facilitate multi-disciplinary and multi-institutional research in a wide scope of research areas, especially the strategic research theme of Cancer research across Hong Kong. 3) To generate and enhance high impact research outputs and grant awards that encompasses (although not limited to) the research areas of oncology, cardiovascular and neurological diseases. 4) To support partnerships with industry, e.g. pharmaceutical industry for pre-clinical drug testing.